Abstract
High linear energy transfer (LET) radiotherapy has an excellent dose distribution and relative biological effectiveness (RBE). As the RBE of particle beams for therapy is important in terms of determining the dose prescription, we have to evaluate an accurate and reliable assessment method. Recently, several particle therapy facilities will open; however, the dose estimation is still not uniform. We have to confirm the quality assurance procedures among several facilities.
Excellent local effect has been already achieved by treatment of monotherapy of carbon ion radiotherapy. The efficacy of carbon ion radiotherapy has been confirmed by taking advantage of the physical and biological properties. In addition, we have to gain the higher survival rate for locally advanced tumor with potentially metastasis. This paper reviews briefly background of carbon ion radiotherapy, biophysical characters, biological characters, and several radiobiological factors. The potential benefit of multimodality treatment will be also discussed to further improve therapeutic outcomes.
Keywords: Radiation biology, high LET, carbon ion radiotherapy, biological quality assurance, multimodality therapy
Current Signal Transduction Therapy
Title: Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Volume: 5 Issue: 3
Author(s): Takeo Takahashi, Yukari Yoshida, Koichi Ando, Hidemasa Kawamura, Masahiko Okamoto, Jun-ichi Saitoh, Hitoshi Ishikawa, Takeshi Ebara, Yoshiyuki Suzuki, Tatsuya Ohno and Takashi Nakano
Affiliation:
Keywords: Radiation biology, high LET, carbon ion radiotherapy, biological quality assurance, multimodality therapy
Abstract: High linear energy transfer (LET) radiotherapy has an excellent dose distribution and relative biological effectiveness (RBE). As the RBE of particle beams for therapy is important in terms of determining the dose prescription, we have to evaluate an accurate and reliable assessment method. Recently, several particle therapy facilities will open; however, the dose estimation is still not uniform. We have to confirm the quality assurance procedures among several facilities.
Excellent local effect has been already achieved by treatment of monotherapy of carbon ion radiotherapy. The efficacy of carbon ion radiotherapy has been confirmed by taking advantage of the physical and biological properties. In addition, we have to gain the higher survival rate for locally advanced tumor with potentially metastasis. This paper reviews briefly background of carbon ion radiotherapy, biophysical characters, biological characters, and several radiobiological factors. The potential benefit of multimodality treatment will be also discussed to further improve therapeutic outcomes.
Export Options
About this article
Cite this article as:
Takahashi Takeo, Yoshida Yukari, Ando Koichi, Kawamura Hidemasa, Okamoto Masahiko, Saitoh Jun-ichi, Ishikawa Hitoshi, Ebara Takeshi, Suzuki Yoshiyuki, Ohno Tatsuya and Nakano Takashi, Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920238
DOI https://dx.doi.org/10.2174/157436210791920238 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy Structural and Bioactive Studies of Halogenated Constituents from Sponges
Current Medicinal Chemistry PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Ultrasound Assisted-synthesis and Biological Evaluation of Piperazinylprop- 1-en-2-yloxy-2H-chromen-2-ones as Cytotoxic Agents
Letters in Drug Design & Discovery Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Cellular Mechanisms that Edit the Immunopeptidome
Current Proteomics Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Cell Elimination as a Strategy for Repair in Acute Spinal Cord Injury
Current Pharmaceutical Design Synthesis of Diflunisal Thiazolidinones as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic Nitrobenzoyloxy-substituted Sesquiterpenes from Spongederived Endozoic Fungus Aspergillus insulicola MD10-2
Current Pharmaceutical Biotechnology Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences Drug Delivery Systems for Prevention and Treatment of Osteoporotic Fracture
Current Drug Targets Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews